



Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)

PATIENT INFORMATION (Complete or Fax Existing Chart)) PRESCRIBER INFORM	PRESCRIBER INFORMATION		
Name:		State License:	Prescriber Name:		
INSURANCE INFORMATION – OR – Send a copy of the patient's prescription/insurance cards (front & back)					
Primary Insurance:		Plan #: Group #: RX Card (PBM):	Plan #:		
CLINICAL INFORMATION					
Primary ICD-10 Code: Secondary ICD-10 Code: Tertiary ICD-10 Code: Transplant Date: Epstein-Barr Virus (EBV): _ Seropositive _ Seronegative or unknown (contra-indicated) Will Nulojix be used with basiliximab induction, mycophenolate mofetil, and corticosteroids? _ Yes _ No Is patient not able to tolerate cyclosporine or tacrolimus due to allergy or intolerance? _ Yes _ No					
NULOJIX® ORDERS					
Prescription type: \square New start \square Restart	☐ Continued therapy Total Doses Received: Date of		Last Injection/Infusion:		
Medication Nulojix® (belatacept) initial dosing Nulojix® (belatacept) maintenance dosing	Dose/Frequency □ 10 mg/kg to nearest 12.5 mg increment IV over 30 minutes on day 1 before transplantation, on day 5 approximately 96 hours after the first dose, and at the end of weeks 2, 4, 8, and 12. □ 5 mg/kg to nearest 12.5 mg-increment IV over 30 minutes at the end of week 16 and every 4 weeks +/- 3 days thereafter □ Other:		Refills Refills:		
SIGNATURE					
We hereby authorize Talis Healthcare LLC to provide all supplies and additional services (nursing/patient training) required to provide and deliver the medicine as prescribed in this referral. Date:					
Prescriber Signature					

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.